Our mission is clear – to create therapeutics that are effective and affordable, for treating infectious diseases that plague the world. This goal includes development of therapeutics and monoclonal antibodies targeting infectious diseases, including the CoronaVirus. Our ultimate objective is to provide such therapeutics to improve health around the world

Enzolytics, Inc. is Texas based biotech company committed to the development and commercialization of its proprietary proteins and monoclonal antibodies for the treatment of infectious diseases, including HIV-1, Hepatitis (A, B, C), rabies, influenza A and B, tetanus and diphtheria. The Company’s multiple therapeutics also are being developed to treat Rheumatoid Arthritis and certain forms of cancer. Our technology for producing fully human monoclonal antibodies is now being employed to produce anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies for treating COVID-19.

Enzolytics is a Texas based biotechnology company with both patented anti-HIV therapeutics and a proprietary methodology for producing fully human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The Company has clinically tested its anti-HIV therapeutics known as ITV-1. ITV-1 is a suspension of Inactivated Pepsin Fragment (IPF), a purified extract of porcine pepsin. ITV-1 has been shown to strengthen the immune system and may be used to facilitate a broad range of applications. ITV-1 has been tested in HIV patients in a clinical trial conducted under the strict guidelines of the European Union where it demonstrated beneficial outcomes. Additionally, the Company has created a proprietary cell line that produces fully human monoclonal antibodies that target and neutralize the HIV virus.

The Company’s scientific team, Harry Zhabilov, Joseph Cotropia MD and Gaurav Chandra MD, pioneered the Company’s proprietary therapeutics for treating infectious diseases, including HIV-1, Hepatitis (A, B, C), rabies, influenza A and B, tetanus and diphtheria. The Company’s therapeutics may also be used to treat Rheumatoid Arthritis and certain forms of cancer.

Enzolytics, Inc. is committed to the development and commercialization of its proprietary therapeutics for the treatment of debilitating infectious diseases. The Company’s technology is broad, including technology for treating HIV-1, Hepatitis (A, B, C), Rheumatoid Arthritis, certain forms of cancer, rabies, influenza A and B, tetanus and diphtheria. The Company’s therapies are also being developed to treat chronic infection and certain forms of cancer.

As a result of the recent acquisition of the biotech company BioClonetics Immunotherapeutics, Inc., Enzolytics is now advancing additional complementary therapeutic platforms for treating infectious diseases, including a focus on production of anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies to treat COVID-19.

The Company protects its technology through an aggressive strategy to cover its intellectual property. The Company’s intellectual property includes:

Issued Patents

Enzolytics is the owner of the following issued U.S. Patents covering its technology relating to a peptide that has been demonstrated in clinical trials to provide anti-HIV-1 retroviral benefit in vivo.

• U.S. Patent No. 7,479,538, issued January 20, 2009, entitled Irreversibly-Inactivated Pepsinogen Fragment and Pharmaceutical Compositions Comprising the Same for Detecting, Preventing and Treating HIV
• U.S. Patent No. 8,066,982, issued November 29, 2011, entitled Irreversibly-Inactivated Pepsinogen Fragment and Pharmaceutical Compositions Comprising the Same for Detecting, Preventing and Treating HIV.